Perrigo Company plc Impairment of Intangible Assets (Excluding Goodwill)
Perrigo Company plc (PRGO) reported Impairment of Intangible Assets (Excluding Goodwill) of $18.50 million for the 3-month period ending 2017-07-01, per its 10-K filed 2019-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2019-02-27
- Perrigo Company plc impairment of intangible assets (excluding goodwill) for the quarter ending 2017-07-01 was $18.50M.
- Perrigo Company plc impairment of intangible assets (excluding goodwill) for the quarter ending 2016-12-31 was $378.60M, a 104.54% increase year-over-year.
- Perrigo Company plc impairment of intangible assets (excluding goodwill) for the quarter ending 2016-10-01 was $866.60M.
- Perrigo Company plc impairment of intangible assets (excluding goodwill) for the quarter ending 2016-04-02 was $273.30M.
- Perrigo Company plc impairment of intangible assets (excluding goodwill) for fiscal 2015 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2017-07-01 | $18.50M 10-K · filed 2019-02-27 | ||
| 2016-12-31 | $378.60M 10-K · filed 2018-03-01 | $1.25B derived: sum of 2 quarters · filed 2018-03-01 | |
| 2016-10-01 | $866.60M 10-K · filed 2018-03-01 | ||
| 2016-04-02 | $273.30M 10-K · filed 2018-03-01 | $458.40M derived: sum of 2 quarters · filed 2018-03-01 | |
| 2015-12-31 | $185.10M 10-K · filed 2018-03-01 | ||
| 2015-06-27 | $0.00 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |